Bangladeshi Rotavirus Vaccine study group. Successful co-administration of a Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age.

Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, Luby S, Breiman RF, Neuzil K, Datta SK, Delem A,Suryakiran PV, Bock HL; Bangladeshi Rotavirus Vaccine study group.

International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), GPO Box-128, Mohakhali, Dhaka 1000, Bangladesh.

Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.

PMID: 19162114 [PubMed - indexed for MEDLINE]